THOMAS I. SWEET MD
Prescription History 1164581732
Internal Medicine - Hematology in San Diego, CA

NPI Status: Active since December 08, 2006

Contact Information

13022 SEAGROVE ST
SAN DIEGO, CA
ZIP 92130
Phone: (858) 350-9703

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for THOMAS I. SWEET MD, an active Hematology specialist practicing in San Diego, CA. Our medical registry currently tracks 20 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,095 documented patient claims. Among these therapy options, the most frequently utilized medication is Abiraterone Acetate, which accounts for 414 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 414
30-Day Fills 424.0
Days Supply 12,720
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills51.1
Peer Average Days Supply1,527
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 762.5% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $65,781.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$158.89

State Avg Cost Per Claim

$1,946.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 57
30-Day Fills 176.3
Days Supply 5,290
CA State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills165.7
Peer Average Days Supply4,950
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,490.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.15

State Avg Cost Per Claim

$27.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 990
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply728
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.5% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $423,208.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,824.49

State Avg Cost Per Claim

$11,990.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Cabometyx

Generic Formulation: Cabozantinib S-MalateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
CA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.9
Peer Average Days Supply625
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $135,238.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,294.43

State Avg Cost Per Claim

$24,238.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat various types of cancer (including kidney, thyroid, liver cancer). Cabozantinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 44.8
Days Supply 1,007
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills36.0
Peer Average Days Supply559
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $958.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.96

State Avg Cost Per Claim

$19.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 37.0
Days Supply 1,110
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills59.9
Peer Average Days Supply1,785
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,179.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.64

State Avg Cost Per Claim

$259.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 349
CA State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills79.9
Peer Average Days Supply1,693
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.2% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $409.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.62

State Avg Cost Per Claim

$22.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 93.9
Days Supply 2,820
CA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills69.5
Peer Average Days Supply2,062
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,366.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.55

State Avg Cost Per Claim

$42.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 385
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply769
Conservative Utilization

This provider writes prescriptions for this formulation 39.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $237,294.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,958.49

State Avg Cost Per Claim

$14,455.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 35.0
Days Supply 1,050
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply728
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,843.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.17

State Avg Cost Per Claim

$1,586.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 588
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.3
Peer Average Days Supply700
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $319,940.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,235.27

State Avg Cost Per Claim

$12,446.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 37.0
Days Supply 1,110
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills111.8
Peer Average Days Supply3,337
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $229.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.12

State Avg Cost Per Claim

$32.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Nubeqa

Generic Formulation: DarolutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
CA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply792
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $177,950.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,897.52

State Avg Cost Per Claim

$12,185.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Darolutamide is used to treat a certain type of prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 262
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply570
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $152.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.48

State Avg Cost Per Claim

$8.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 430
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply245
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 27.3% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $407.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.55

State Avg Cost Per Claim

$21.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Pradaxa

Generic Formulation: Dabigatran Etexilate MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
CA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills130.8
Peer Average Days Supply3,890
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,960.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$108.93

State Avg Cost Per Claim

$487.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Therapeutic Applications

Dabigatran is used to prevent stroke and harmful blood clots (such as in your legs or lungs) if you have a certain type of irregular heartbeat (atrial fibrillation). Dabigatran is also used to treat blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) and to reduce the risk of them occurring again. This medication may also be used to prevent these blood clots from forming after hip replacement surgery. Dabigatran is an anticoagulant that works by blocking a certain substance (a clotting protein called thrombin) in your blood. This helps to keep blood flowing smoothly in your body. Dabigatran should not be used to prevent blood clots from forming after artificial heart valve replacement. If you have had heart valve surgery, talk to your doctor about the best medication for you. Do not stop taking any medication, including dabigatran, without talking to your doctor first.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 227
30-Day Fills 388.7
Days Supply 11,622
CA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills52.2
Peer Average Days Supply1,075
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 467.5% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,146.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.45

State Avg Cost Per Claim

$8.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 160
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply353
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $214.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.52

State Avg Cost Per Claim

$18.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 37.3
Days Supply 1,120
CA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills83.0
Peer Average Days Supply2,479
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.8% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $457.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.20

State Avg Cost Per Claim

$36.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 71
30-Day Fills 71.0
Days Supply 2,106
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply925
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 136.7% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $813,745.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,461.20

State Avg Cost Per Claim

$12,773.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like THOMAS I. SWEET MD provides transparency into local medical care patterns within San Diego, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.